Valuation: Abivax

Market Cap 7.88B 9.1B 7.45B 6.76B 12.68B 873B 12.75B 88.96B 34.37B 443B 34.17B 33.42B 1,411B P/E 2026 *
-25.5x
P/E 2027 * -30x
Enterprise Value 6.79B 7.83B 6.41B 5.82B 10.91B 751B 10.98B 76.57B 29.59B 381B 29.41B 28.76B 1,214B EV / Sales 2026 *
96.7x
EV / Sales 2027 * 87.1x
Free-Float
92.81%
Yield 2026 *
-
Yield 2027 * -
1 day-3.62%
1 week-10.62%
Current month-7.28%
1 month-11.93%
3 months+8.26%
6 months-15.62%
Current year-24.88%
1 week 89
Extreme 89
101.7
1 month 89
Extreme 89
105.8
Current year 60.45
Extreme 60.45
139
1 year 60.45
Extreme 60.45
139
3 years 4.51
Extreme 4.51
139
5 years 4.51
Extreme 4.51
139
10 years 4.51
Extreme 4.51
139
Manager TitleAgeSince
Chief Executive Officer 68 2023-05-04
Director of Finance/CFO 63 2017-01-01
Chief Tech/Sci/R&D Officer - 2023-09-30
Director TitleAgeSince
Chairman 66 2022-08-15
Chairman 68 2023-05-04
Director/Board Member 60 2023-07-10
Date Insider Type Main position Quantity % Market Cap. Importance
7/15/26 Sell

Chairman

-3,375 0.0042%
7/11/26 Exercice

Chief Executive Officer

17,728 0.0222%
7/11/26 Exercice

Chairman

12,500 0.0157%
Change 5-day change 1-year change 3-year change Capi.($)
-3.62%-10.62%+31.85%+450.18% 9.44B
+0.22%+0.07%-1.90%+8.24% 45.81B
-0.32%+4.61%+43.90%+26.98% 44.39B
-4.36%-5.66%+338.30%+516.88% 43.91B
+0.46%-0.83%+6.38%+73.76% 39.4B
-0.17%-3.22%+10.29%+38.69% 31.26B
-0.65%+5.14%+25.61%+120.17% 17.32B
+3.30%-5.03% - - 15.75B
+1.66%+5.30%+19.25%+34.93% 14.73B
+0.86%+9.05%+0.47%-33.54% 13.31B
Average -0.26%-0.72%+52.68%+137.37% 27.53B
Weighted average by Cap. -0.51%-0.63%+70.59%+134.02%

Financials

2026 *2027 *
Net sales 70.18M 80.98M 66.33M 60.22M 113M 7.77B 114M 792M 306M 3.94B 304M 297M 12.56B 79.52M 91.76M 75.16M 68.23M 128M 8.8B 129M 897M 347M 4.46B 345M 337M 14.23B
Net income -265M -306M -251M -228M -426M -29.35B -429M -2.99B -1.16B -14.89B -1.15B -1.12B -47.45B -231M -266M -218M -198M -371M -25.54B -373M -2.6B -1.01B -12.96B -1B -978M -41.29B
Net Debt -1.1B -1.27B -1.04B -942M -1.77B -122B -1.78B -12.39B -4.79B -61.65B -4.76B -4.65B -197B -956M -1.1B -904M -820M -1.54B -106B -1.55B -10.79B -4.17B -53.68B -4.14B -4.05B -171B
Logo Abivax
Abivax is a clinical-stage biotechnology company focused on the development of therapeutics that exploit the body's natural regulatory mechanisms to stabilize the immune response in patients suffering from chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderate to severe active ulcerative colitis.
Employees
80
Date Price Change Volume
26-09-16 €90.45 -3.62% 159,819
26-09-15 €93.85 -5.82% 126,106
26-09-14 €99.65 -1.63% 81,653
26-09-11 €101.30 +1.00% 92,586
26-09-10 €100.30 -0.89% 92,399
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
90.45EUR
Average target price
137.98EUR
Spread / Average Target
+52.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABVX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!